"While product continues to be manufactured and shipped, patients in some areas of the country will experience delays with these doses," Novo Nordisk said in a statement, adding that patients "concerned with continuity of treatment, should contact their healthcare provider."
Studies have shown that patients who discontinue semaglutide, will regain two-thirds of the weight they lost within the subsequent year, according to McGowan. chronic, progressive, and relapsing diseaseThis will ultimately create a barrier "for patients who may be opposed to using a medication long-term and for healthcare providers who, unfortunately, often do not view obesity as the chronic disease that it is," he continued.
Even though this drug is used to treat a medical disease, according to McGowan and Mullally, patients still run into insurance issues.Insurance coverage"Only a small minority of commercial insurance programs cover Wegovy, and government insurance explicitly excludes coverage of anti-obesity drugs," he continued.
Those in search of weight loss product with no insurance coverage Message me directly Ozempic Mounjaro Wegovy Duromine Saxenda
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: clevelanddotcom - 🏆 301. / 63 Read more »
Source: WSJhealth - 🏆 413. / 53 Read more »